461432-22-4

Basic information

• Product Name: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
• Synonyms: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone;Methanone, (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)-;(5-broMo-2-chlorophenyl)(4-ethoxyphenyl)-;5-broMo-2-chloro-4'-ethoxybenzophenone;(5-BroMo-2-chlorophenyl)(4-ethoxypheny)Methanone;Dapagliflozin iMpurity A;Dapagliflozin Intermediate I;Dapagliflozin Impurity 18
• CAS NO: 461432-22-4
• Molecular Formula: C₁₅H₁₂BrClO₂
• Molecular Weight: 339.61
• EINECS: 1592732-453-0
• Product Categories: API intermediates
• Mol File: 461432-22-4.mol
• Article Data: 43

Chemical Properties

• Boiling Point: 439.162 °C at 760 mmHg
• Flash Point: 219.397 °C
• Appearance: /
• Density: 1.437
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone(461432-22-4)
• EPA Substance Registry System: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone(461432-22-4)

Safety Data

• Hazardous Substances Data: 461432-22-4(Hazardous Substances Data)

Usage

Description

(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique molecular structure, which features a methanone group and two distinct aromatic rings, one with a bromine and chlorine substitution, and the other with an ethoxy group. (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone plays a significant role in the development of novel drugs due to its versatile chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is used as a key intermediate in the synthesis of Dapagliflozin, a novel and selective sodium-glucose co-transporter type II (SGLT2) inhibitor. (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is essential for the development of Dapagliflozin, which is a potent drug used in the treatment of type 2 diabetes. It helps to lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys, thereby promoting its excretion through urine.
The use of (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone in the synthesis of Dapagliflozin highlights its importance in the pharmaceutical industry, as it contributes to the development of innovative treatments for chronic diseases like diabetes. Its unique chemical properties and reactivity make it a valuable component in the design and synthesis of new drugs, potentially leading to the discovery of additional therapeutic agents in the future.

InChI:InChI=1/C15H12BrClO2/c1-2-19-12-6-3-10(4-7-12)15(18)13-9-11(16)5-8-14(13)17/h3-9H,2H2,1H3

Upstream product

• 79-37-8 oxalyl dichloride 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 103-73-1 Phenetole 
• 108-95-2 phenol 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 915095-85-1 (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone 
• 141-52-6 sodium ethanolate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 25117-74-2 4-ethoxybenzonitrile 
• 10031-82-0 4-ethoxybenzaldehyde 
• 106-40-1 4-bromo-aniline 
• 462-06-6 fluorobenzene 
• 64-17-5 ethanol 

Downstream Products

• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 1204219-31-7 4-bromo-1-chloro-2-((4-ethoxyphenyl)methyl-d2)benzene 
• 1280647-32-6 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanol 
• 1298086-15-3 2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene 
• 1298086-16-4 2-(allyloxy(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 
• 1360569-36-3 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-( trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-35-2 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-37-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-38-5 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-39-6 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-40-9 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360568-77-9 4-bromo-l-chloro-2-(4-((1-ethylcyclobutyl)methoxy)benzyl)benzene 
• 1360568-78-0 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-((1-ethylcyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN

A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more other active substances and methods for making the same.

Preparation method of polysubstituted diphenyl ketone

The preparation method comprises the following steps: (1) a compound represented by the formula II and a compound shown III as a raw material; and synthesizing the compound as shown IV. (2) The compound of Formula IV is subjected to Fries rearrangement to produce a compound of Formula V. (3) A compound of Formula V is subjected to a halogenation reaction in contact with a halogenation reagent to prepare a multi-substituted diphenyl ketone represented by Formula I. Wherein, X is selected from H, F, Cl, Br, I. R1 Selected H from F Cl, Br I are RO selected R from H, C1 - C6. X is selected from F, Cl, Br, and i. The present invention is capable of improving the yield and selectivity of the target product.

Method for preparing dapagliflozin intermediate by one-pot method

The invention discloses a method for preparing a dapagliflozin intermediate by a one-pot method, and the method comprises the following steps: reacting 5-bromo-2-chlorobenzoic acid with phenetole in the presence of an oxidant and a catalyst for a period of time, and performing purifying to obtain the dapagliflozin intermediate (5-bromo-2-chlorphenyl) (4-ethoxyphenyl) ketone. The method provided by the invention is high in yield, simplifies the process steps of the traditional synthesis method, makes the process simpler, reduces the reaction cost and impurity content, improves the purity and yield, and better conforms to the industrialization standard of benefit maximization.